Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyzeRCTsin oncology

被引:18
|
作者
Ristl, Robin [1 ]
Ballarini, Nicolas M. [1 ]
Goette, Heiko [2 ]
Schueler, Armin [2 ]
Posch, Martin [1 ]
Koenig, Franz [1 ]
机构
[1] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria
[2] Merck Healthcare KGaA, Darmstadt, Germany
关键词
LOG-RANK TEST; FLEMING-HARRINGTON CLASS; SEQUENTIAL-TESTS; END-POINTS; WEIGHTS;
D O I
10.1002/pst.2062
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the analysis of survival times, the logrank test and the Cox model have been established as key tools, which do not require specific distributional assumptions. Under the assumption of proportional hazards, they are efficient and their results can be interpreted unambiguously. However, delayed treatment effects, disease progression, treatment switchers or the presence of subgroups with differential treatment effects may challenge the assumption of proportional hazards. In practice, weighted logrank tests emphasizing either early, intermediate or late event times via an appropriate weighting function may be used to accommodate for an expected pattern of non-proportionality. We model these sources of non-proportional hazards via a mixture of survival functions with piecewise constant hazard. The model is then applied to study the power of unweighted and weighted log-rank tests, as well as maximum tests allowing different time dependent weights. Simulation results suggest a robust performance of maximum tests across different scenarios, with little loss in power compared to the most powerful among the considered weighting schemes and huge power gain compared to unfavorable weights. The actual sources of non-proportional hazards are not obvious from resulting populationwise survival functions, highlighting the importance of detailed simulations in the planning phase of a trial when assuming non-proportional hazards.We provide the required tools in a software package, allowing to model data generating processes under complex non-proportional hazard scenarios, to simulate data from these models and to perform the weighted logrank tests.
引用
收藏
页码:129 / 145
页数:17
相关论文
共 50 条
  • [1] Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Keynote and panel discussion on communicating heterogeneous treatment effects across populations
    Heyward, James
    Lolic, Milena
    Spong, Catherine
    Atkins, David
    Pennello, Gene
    Varadhan, Ravi
    PHARMACEUTICAL STATISTICS, 2021, 20 (05) : 965 - 978
  • [2] A novel design for randomized immuno-oncology clinical trials with potentially delayed treatment effects
    He, Pei
    Su, Zheng
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2015, 1 : 28 - 31
  • [3] On treatment of tuberculosis in heterogeneous populations
    Murphy, BM
    Singer, BH
    Kirschner, D
    JOURNAL OF THEORETICAL BIOLOGY, 2003, 223 (04) : 391 - 404
  • [4] Statistical treatment rules for heterogeneous populations
    Manski, CF
    ECONOMETRICA, 2004, 72 (04) : 1221 - 1246
  • [5] Adaptive promising zone design for cancer immunotherapy with heterogeneous delayed treatment effect
    Li, Bosheng
    Yan, Fangrong
    Jiang, Depeng
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2024,
  • [6] Customizing treatment to patient populations
    Brown, Robert S., Jr.
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2007, 4 (Suppl 1): : S3 - S9
  • [7] Customizing treatment to patient populations
    Robert S Brown
    Nature Clinical Practice Gastroenterology & Hepatology, 2007, 4 : S3 - S9
  • [8] PATIENT PREFERENCES FOR TREATMENT ATTRIBUTES IN ONCOLOGY
    Rodriguez, A. M.
    Philpott, S.
    Batchelder, L.
    VALUE IN HEALTH, 2022, 25 (07) : S569 - S569
  • [9] Heterogeneous treatment effects and bias in the analysis of the stepped wedge design
    Lindner, Stephan
    McConnell, K. John
    HEALTH SERVICES AND OUTCOMES RESEARCH METHODOLOGY, 2021, 21 (04) : 419 - 438
  • [10] Heterogeneous treatment effects and bias in the analysis of the stepped wedge design
    Stephan Lindner
    K. John McConnell
    Health Services and Outcomes Research Methodology, 2021, 21 : 419 - 438